Essential role of nuclear medicine technology in tositumomab and 131I-tositumomab therapeutic regimen for non-Hodgkin's lymphoma.
Nuclear medicine technology has traditionally focused on diagnostic imaging, with therapeutics left mostly to other medical disciplines. However, after many years in development, radioimmunotherapy (RIT) has finally become a clinical reality in many nuclear medicine departments. The nuclear medicine technologist is a key player in the successful implementation of RIT. Delivery of a therapeutic regimen of tositumomab and (131)I-tositumomab provides a model for the technologist's roles and responsibilities in the developing field of RIT. This article examines the clinical rationale, logistic requirements, and imaging and dosimetry procedures required by this treatment regimen. Upon completion of this article, the reader should be able to describe the target patient population and identify the roles and responsibilities of various members of the treatment team. The reader will also gain an understanding of the treatment process, including drug administration, imaging, and therapeutic dose calculations.
Cole
William C
WC
University of Colorado Health Sciences Center, Denver, Colorado, USA.
Barrickman
Jennifer
J
Bloodworth
Glen
G
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009683:Nuclear Medicine; D011874:Radiometry; D011795:Surveys and Questionnaires; D051598:Whole Body Imaging
D000911:Antibodies, Monoclonal; C119496:tositumomab I-131